Wiep R. De Ligny

Wiep R. De Ligny

Auto-generated profile, based on publicly available information

Wiep R. De Ligny

Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2022 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
WLWiep Ligny
Wiep Ligny
RSRoos M Smits
Roos M Smits
RMRebecca Mackenzie-Proctor
Rebecca Mackenzie-Proctor
VJVanessa Jordan
Vanessa Jordan
KFKathrin Fleischer
Kathrin Fleischer
MSMarian G Showell
Marian G Showell

1 February 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
WLWiep R. De Ligny
Wiep R. De Ligny
MKManon Heleen Kerkhof
Manon Heleen Kerkhof
ARAlejandra Ruiz-Zapata
Alejandra Ruiz-Zapata

1 January 2023 in Human Reproduction Open
Verified
Journal Article
Open access
PDF file
WLWiep R de Ligny
Wiep R de Ligny
KFKathrin Fleischer
Kathrin Fleischer
HGHilde Grens
Hilde Grens
DBDidi D M Braat
Didi D M Braat
JBJan Peter de Bruin
Jan Peter de Bruin
What is the evidence for over-the-counter antioxidant supplements for male infertility? Less than half of over-the-counter antioxidant supplements for male fertility patients have been tested in a clinical trial, and the available clinical trials are generally of poor quality. The prevalence of male infertility is rising and, with this, the market for supplements claiming to improve male fertility is expanding. Up to now, there is limited data on the evidence for these over-the-counter supplements. Amazon, Google Shopping and other relevant shopping websites were searched on 24 June 2022 with the following terms: ‘supplements’, ‘antioxidants’, ‘vitamins’, AND ‘male fertility’, ‘male infertility’, ‘male subfertility’, ‘fertility men’, ‘fertility man’. All supplements with a description of ingredients in English, Dutch, French, Spanish, or German were included. Subsequently, Pubmed and Google Scholar were searched for studies that included the supplements. Inclusion criteria were supplements with antioxidant properties, of which the main purpose was to improve male fertility. Included supplements must be available without a doctor’s prescription. Supplements containing plant extracts were excluded, as well as supplements of which the content or dosage was not clear. The ingredients, dosage, price and health claims of the supplements were recorded. We assessed whether substances in the supplements exceeded the recommended dietary allowance (RDA) or tolerable upper intake level (UL). All clinical trials and animal studies investigating included supplements were selected for this review. Clinical trials were assessed for risk of bias with a risk of bias tool appropriate for the study design. There were 34 eligible antioxidant supplements found, containing 48 different active substances. The average price per 30 days was 53.10 US dollars. Most of the supplements (27/34, 79%) contained substances in a dosage exceeding the recommended daily allowance (RDA). All manufacturers of the supplements made health claims related to the improvement of sperm quality or male fertility. For 13 of the 34 supplements (38%), published clinical trials were available, and for one supplement, only an animal study was found. The overall quality of the included studies was poor. Only two supplements were tested in a good quality clinical trial. As a consequence of searching shopping websites, a comprehensive search strategy could not be formulated. Most supplements were excluded because they contained plant extracts or because supplement information was not available (in an appropriate language). This is the first review that gives an insight into the market of male fertility supplements as available to infertility patients and other men seeking to improve their fertility. Earlier reviews have focused only on supplements with published clinical trials. However, we show that more than half of the supplements have not been tested in a clinical trial. To our knowledge, this review is the first to assess the dosage of supplements in relation to the RDA. In agreement with the literature, we found that the evidence on male fertility supplements is generally of poor quality. This review should urge pharmaceutical companies to evaluate their products in randomized controlled trials in order to provide people with substantiated information. The research position of W.R.d.L. is funded by an unrestricted grant from Goodlife Pharma. W.R.d.L., K.F., and J.P.d.B. are in the research team of a clinical trial on Impryl®, one of the supplements included in this review. N/A.

2 September 2025 in JAMA Network Open
Verified
Journal Article
Open access
WLWiep R. de Ligny
Wiep R. de Ligny
JBJan Peter de Bruin
Jan Peter de Bruin
RSRoos M. Smits
Roos M. Smits
IGIlse G. F. Goovaerts
Ilse G. F. Goovaerts
KPKris Peeters
Kris Peeters
KFKathrin Fleischer
Kathrin Fleischer
Importance: Treatments for men seeking fertility care are limited. Antioxidant supplements have been widely studied as a new treatment option, but these studies have had conflicting results.Objective: To assess whether treatment of men seeking fertility care with an antioxidant supplement can improve semen quality and pregnancy rates compared with a placebo.Design, Setting, and Participants: The SUMMER trial was a multicenter, double-blind, placebo-controlled randomized clinical trial conducted in 21 hospitals and private fertility clinics in the Netherlands. Male patients in these centers were enrolled between May 2018 and February 2024, and follow-up of the primary outcome was completed in December 2024. Eligible participants were men aged 18 to 50 years with female partners aged 18 to 43 years, who sought fertility care and were advised to undergo expectant management, treatment with intrauterine insemination, in vitro fertilization (IVF), or intracytoplasmic sperm injection (ICSI). Couples treated with ovulation induction only or IVF for bilateral tubal pathology were excluded. The men were randomly assigned to receive an antioxidant supplement or a placebo. Intention-to-treat analysis was performed for all outcomes.Interventions: The antioxidant supplement (Impryl) was a tablet to be taken daily for 6 months. It contained betaine (200 mg), L-cystine (200 mg), niacin (16 mg), zinc (10 mg), vitamin B6 (1.4 mg), vitamin B2 (1.4 mg), folic acid (400 µg), and vitamin B12 (2.5 µg). The placebo tablet and its packaging were identical to those of the antioxidant supplement. All participating couples received standard infertility care.Main Outcomes and Measures: The primary outcome was ongoing pregnancy conceived within 6 months after randomization. Secondary outcomes included semen parameters, sperm DNA fragmentation, fertilization and embryo utilization rates after IVF or ICSI, biochemical and clinical pregnancy rates, first-trimester pregnancy loss, ectopic pregnancy rate, cumulative number of pregnancies, time to pregnancy, and adverse events.Results: A total of 1171 men (median [IQR] age, 34 [31-38] years; female partners’ median [IQR] age, 32 [30-35] years) were included in the data analysis, of whom 591 were in the antioxidant supplement group and 580 were in the placebo group. Ongoing pregnancy rate within 6 months was not significantly different between the 2 groups (193 of 571 [33.8%] vs 208 of 555 [37.5%]; adjusted odds ratio [AOR], 0.85 [95% CI, 0.66-1.09]; P = .20). Within the window of optimal treatment effect between 4 and 6 months (considering a spermatogenesis cycle of 72 days), ongoing pregnancy rate was significantly lower in the antioxidant supplement group compared with the placebo group (69 of 446 [15.5%] vs 95 of 442 [21.5%]; AOR, 0.66 [95% CI, 0.47-0.94]; P = .02). There were no significant between-group differences for the secondary outcomes.Conclusions and Relevance: This randomized clinical trial found that ongoing pregnancy rates did not improve with the antioxidant supplement compared with a placebo. Therefore, the investigators do not support its use in men seeking fertility care.Trial Registration: ClinicalTrials.gov Identifier: NCT03337360

1 March 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
WLWiep R. De Ligny
Wiep R. De Ligny
MKManon Heleen Kerkhof
Manon Heleen Kerkhof
ARAlejandra Ruiz-Zapata
Alejandra Ruiz-Zapata

26 October 2025 in Andrology
Verified
Journal Article
Open access
WLWiep R. de Ligny
Wiep R. de Ligny
KFKathrin Fleischer
Kathrin Fleischer
HGHilde Grens
Hilde Grens
DBDidi D. M. Braat
Didi D. M. Braat
IAInger L. Abma
Inger L. Abma
JBJan Peter de Bruin
Jan Peter de Bruin
Background: An unhealthy lifestyle negatively affects male fertility. Despite this, men that are part of an infertile couple often fail to improve their lifestyle and evidence on influencing factors is limited. Objectives: To identify facilitators and barriers involved in lifestyle changes of men seeking fertility care and in lifestyle counseling by fertility health care providers (HCPs). Materials and Methods: A mixed‐methods study was performed including semi‐structured interviews with 14 men seeking fertility care and seven fertility HCPs. Fifty other men completed a questionnaire evaluating various aspects of lifestyle change. Eligible participants were men part of an infertile couple and met at least one lifestyle criterion: BMI ≥ 25 kg/m 2 , smoker, alcohol use of ≥ 7 units/week, and recreational drug use. Included HCPs provided lifestyle counseling to infertile couples. Results: The most important facilitators for lifestyle changes in men seeking fertility care are the wish to improve their chances to father a child and their partner's support. The most important barriers are stress, a busy life, an unhealthy lifestyle being part of social activities, and normal semen quality. HCPs experienced limited time, unclear and insufficient scientific evidence on lifestyle and male infertility, and lack of uniform care as barriers. Professional responsibility and societal factors were facilitators. Discussion: HCPs could use these results to improve and personalize lifestyle counseling of men seeking fertility care. For example, by emphasizing the impact of lifestyle on pregnancy loss and offspring in men with normal semen quality. This study is limited by its small sample size and its confinement to a Dutch context. Conclusion: This study identifies previously unknown facilitators and barriers for lifestyle changes in men seeking fertility care. It also reveals barriers experienced by HCPs when counseling male patients about lifestyle. These results should inspire fertility departments to (re)design lifestyle interventions and policies for men seeking fertility care.